Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $368000.0.

  • Cartesian Therapeutics' Change in Receivables rose 10135.24% to $368000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year decrease of 585217.39%. This contributed to the annual value of -$5.0 million for FY2024, which is 58842.98% down from last year.
  • Cartesian Therapeutics' Change in Receivables amounted to $368000.0 in Q3 2025, which was up 10135.24% from -$1.4 million recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year Change in Receivables high stood at $30.0 million for Q2 2024, and its period low was -$27.2 million during Q3 2024.
  • Over the past 5 years, Cartesian Therapeutics' median Change in Receivables value was -$329000.0 (recorded in 2022), while the average stood at -$342210.5.
  • As far as peak fluctuations go, Cartesian Therapeutics' Change in Receivables skyrocketed by 1359186.99% in 2022, and later tumbled by 548726.9% in 2024.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Change in Receivables stood at $2.6 million in 2021, then crashed by 112.7% to -$329000.0 in 2022, then soared by 395.44% to $972000.0 in 2023, then plummeted by 507.1% to -$4.0 million in 2024, then skyrocketed by 109.3% to $368000.0 in 2025.
  • Its last three reported values are $368000.0 in Q3 2025, -$1.4 million for Q2 2025, and $893000.0 during Q1 2025.